News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zhejiang Beta's Conmana, a Cancer Drug, is a Big Winner


8/26/2013 8:51:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

August 23, 2013 -- In 2011, Zhejiang Beta received CFDA approval for Conmana (icotinib), an oral EGFR tyrosine kinase inhibitor that is indicated as a treatment for non-small cell lung cancer. Conmana is a me-too drug, and its clinical trial results were more or less in line with first-gen members of the class. However, its development costs ($20-$30 million) were only a small fraction of its big pharma competitors (up to $1 billion), and development time, from start to finish, was a short eight years.As a result, Zhejiang Beta can offer its drug at a price that undercuts the cost of its big pharma competition by 33%. More details....

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES